Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup

References

• Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual report. Clin Toxicol. 2019;57(12):1220–1413.
   PubMed Web of Science ®Google Scholar
• Samtleben W. Successful plasmapheresis in severe diltiazem poisoning. Dtsch Med Wochenschr. 1995;120(28–29):1023.
   PubMed Web of Science ®Google Scholar
• Akinci E, Akilli NB, Koylu R, et al. Successful resuscitation of a patient with continuous venovenous hemodiafiltration following intoxication from verapamil and trandolapril. Kaohsiung J Med Sci. 2014;30(6):321–322.
   PubMed Web of Science ®Google Scholar
• Pichon N, Francois B, Chevreuil C, et al. Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication. Clin Toxicol. 2006;44(2):195–196.
   Web of Science ®Google Scholar
• Ramanathan K, Mohanty B, Tang S, et al. Extracorporeal therapy for amlodipine poisoning. J Artif Organs. 2020;23(2):183–186.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Nolin TD, Lavergne V, EXTRIP workgroup, et al. Blood purification in toxicology: nephrology's ugly duckling. Adv Chronic Kidney Dis. 2011;18(3):160–166.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Nolin TD, Goldfarb DS, et al. Extracorporeal treatment for thallium poisoning: recommendations from the EXTRIP Workgroup. CJASN. 2012;7(10):1682–1690.
   PubMed Web of Science ®Google Scholar
• Lavergne V, Nolin TD, Hoffman RS, et al. The EXTRIP (extracorporeal treatments in poisoning) workgroup: guideline methodology. Clin Toxicol. 2012;50(5):403–413.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Yates C, Galvao TF, EXTRIP workgroup, et al. Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol. 2014;52(10):993–1004.
   PubMed Web of Science ®Google Scholar
• Gosselin S, Juurlink DN, Kielstein JT, Extrip Workgroup, et al. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clin Toxicol. 2014;52(8):856–867.
   Web of Science ®Google Scholar
• Lavergne V, Ouellet G, Bouchard J, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: methodology. Semin Dial. 2014;27(4):407–414.
   PubMed Web of Science ®Google Scholar
• Mactier R, Laliberte M, Mardini J, EXTRIP Workgroup, et al. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis. 2014;64(3):347–358.
   PubMed Web of Science ®Google Scholar
• Yates C, Galvao T, Sowinski KM, EXTRIP workgroup, et al. Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup. Semin Dial. 2014;27(4):381–389.
   PubMed Web of Science ®Google Scholar
• Decker BS, Goldfarb DS, Dargan PI, on behalf of the EXTRIP Workgroup, et al. Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP Workgroup. CJASN. 2015;10(5):875–887.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Laliberte M, Nolin TD, EXTRIP Workgroup, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol. 2015;53(5):454–465.
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Wiegand TJ, Liu KD, on behalf of the EXTRIP workgroup, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol. 2015;53(4):215–229.
   Web of Science ®Google Scholar
• Juurlink DN, Gosselin S, Kielstein JT, EXTRIP Workgroup, et al. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP Workgroup. Ann Emerg Med. 2015;66(2):165–181.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Crit Care Med. 2015;43(2):461–472.
   PubMed Web of Science ®Google Scholar
• Anseeuw K, Mowry JB, Burdmann EA, EXTRIP Workgroup, et al. Extracorporeal treatment in phenytoin poisoning: systematic review and recommendations from the EXTRIP (extracorporeal treatments in poisoning) Workgroup. Am J Kidney Dis. 2016;67(2):187–197.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Burdmann EA, Anseeuw K, EXTRIP Workgroup, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol. 2016;54(2):103–114.
   PubMed Web of Science ®Google Scholar
• Berling I, King JD, Shepherd G, EXTRIP workgroup, et al. Extracorporeal treatment for chloroquine, hydroxychloroquine, and quinine poisoning: systematic review and recommendations from the EXTRIP Workgroup. J Am Soc Nephrol. 2020;31(10):2475–2489.
   PubMed Web of Science ®Google Scholar
• Calello DP, Liu KD, Wiegand TJ, Extracorporeal Treatments in Poisoning Workgroup, et al. Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015;43(8):1716–1730.
   PubMed Web of Science ®Google Scholar
• Hanyok JJ, Chow MS, Kluger J, et al. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol. 1988;28(9):831–836.
   PubMed Web of Science ®Google Scholar
• Martre H, Sari R, Taburet AM, et al. Haemodialysis does not affect the pharmacokinetics of nifedipine. Br J Clin Pharmacol. 1985;20(2):155–158.
   PubMed Web of Science ®Google Scholar
• Faulkner JK, McGibney D, Chasseaud LF, et al. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22(1):21–25.
   PubMed Web of Science ®Google Scholar
• Boyd RA, Chin SK, Don-Pedro O, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther. 1989;46(4):408–419.
   PubMed Web of Science ®Google Scholar
• Batalis NI, Harley RA, Schandl CA. Verapamil toxicity: an unusual case report and review of the literature. Am J Forensic Med Pathol. 2007;28(2):137–140.
   PubMed Web of Science ®Google Scholar
• Schoffstall JM, Spivey WH, Gambone LM, et al. Effects of calcium channel blocker overdose-induced toxicity in the conscious dog. Ann Emerg Med. 1991;20(10):1104–1108.
   PubMed Web of Science ®Google Scholar
• Ochs HR, Knuchel M. Pharmacokinetics and absolute bioavailability of diltiazem in humans. Klin Wochenschr. 1984;62(7):303–306.
   PubMedGoogle Scholar
• McAllister RG, Jr., Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982;31(4):418–426.
   PubMed Web of Science ®Google Scholar
• Zachariah PK, Moyer TP, Theobald HM, et al. The pharmacokinetics of racemic verapamil in patients with impaired renal function. J Clin Pharmacol. 1991;31(1):45–53.
   PubMed Web of Science ®Google Scholar
• Ahmed JH, Grant AC, Rodger RSC, et al. Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol. 1991;32(1):57–62.
   PubMed Web of Science ®Google Scholar
• Mooy J, Schols M, V Baak M, et al. Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol. 1985;28(4):405–410.
   PubMed Web of Science ®Google Scholar
• Larsson R, Karlberg BE, Gelin A, et al. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J Clin Pharmacol. 1990;30(11):1020–1030.
   PubMed Web of Science ®Google Scholar
• Edgar B, Hoffmann KJ, Lundborg P, et al. distribution and elimination of felodipine in man. Drugs. 1985;29 (Suppl 2):9–15.
   PubMed Web of Science ®Google Scholar
• Edgar B, Regardh CG, Attman PO, et al. Pharmacokinetics of felodipine in patients with impaired renal function. Br J Clin Pharmacol. 1989;27(1):67–74.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Robieux I, Fantin D, et al. Non-linear pharmacokinetics of high-dose intravenous verapamil. Br J Clin Pharmacol. 1997;44(3):255–260.
   PubMed Web of Science ®Google Scholar
• Tawashi M, Marc-Aurele J, Bichet D, et al. Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. Biopharm Drug Dispos. 1991;12(2):105–112.
   PubMed Web of Science ®Google Scholar
• Pozet N, Brazier JL, Aissa AH, et al. Pharmacokinetics of diltiazem in severe renal failure. Eur J Clin Pharmacol. 1983;24(5):635–638.
   PubMed Web of Science ®Google Scholar
• Buur T, Larsson R, Regardh CG, et al. Pharmacokinetics of felodipine in chronic hemodialysis patients. J Clin Pharmacol. 1991;31(8):709–713.
   PubMed Web of Science ®Google Scholar
• Reynaud C, Eysseric-Guerin H, Bonadona A, et al. Toxic death caused by amlodipin and olmesartan: A case report with pharmacobezoard. Toxicol Anal Clin. 2016;28(4):286–293.
   Web of Science ®Google Scholar
• Luomanmaki K, Tiula E, Kivisto KT, et al. Pharmacokinetics of diltiazem in massive overdose. Ther Drug Monit. 1997;19(2):240–242.
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Neuvonen PJ, Tarssanen L. Pharmacokinetics of verapamil in overdose. Hum Exp Toxicol. 1997;16(1):35–37.
   PubMed Web of Science ®Google Scholar
• Anthony T, Jastremski M, Elliott W, et al. Charcoal hemoperfusion for the treatment of a combined diltiazem and metoprolol overdose. Ann Emerg Med. 1986;15(11):1344–1348.
   PubMed Web of Science ®Google Scholar
• Saulnier F, Durocher A, Klug D. Intoxication massive par le diltiazem. Intérêt de welcwell’hémoperfusion. Rean Soins Intens Med Urg. 1989;5:470.
   Google Scholar
• Roberts DM, Roberts JA, Boots RJ, et al. Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. Anaesthesia. 2008;63(7):714–718.
   PubMed Web of Science ®Google Scholar
• Durward A, Guerguerian AM, Lefebvre M, et al. Massive diltiazem overdose treated with extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2003;4(3):372–376.
   PubMedGoogle Scholar
• Belleflamme M, Hantson P, Gougnard T, et al. Survival despite extremely high plasma diltiazem level in a case of acute poisoning treated by the molecular-adsorbent recirculating system. Eur J Emer Med. 2012;19(1):59–61.
   PubMed Web of Science ®Google Scholar
• Schiffl H, Ziupa J, Schollmeyer P. Clinical features and management of nifedipine overdosage in a patient with renal insufficiency. J Toxicol Clin Toxicol. 1984;22(4):387–395.
   PubMed Web of Science ®Google Scholar
• Maddi S, Yamsani MR, Seeling A, et al. Stereoselective plasma protein binding of amlodipine. Chirality. 2010;22(2):262–266.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Gutkowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S67–S71.
   PubMed Web of Science ®Google Scholar
• Stopher DA, Beresford AP, Macrae PV, et al. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol. 1988;12(Suppl 7):S55–S59.
   PubMed Web of Science ®Google Scholar
• Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol. 1994;73(3):A10–7A.
   Web of Science ®Google Scholar
• Vincent J, Harris SI, Foulds G, et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol. 2000;50(5):455–463.
   PubMed Web of Science ®Google Scholar
• Laher MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol. 1988;12(suppl 7):S60–S3.
   PubMed Web of Science ®Google Scholar
• Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol. 1996;51(2):189–193.
   PubMed Web of Science ®Google Scholar
• Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195.
   PubMed Web of Science ®Google Scholar
• Ando M, Nakasako S, Ariyoshi K, et al. Re-elevation of serum amlodipine level after lipid emulsion therapy in an overdose case. J Clin Pharm Ther. 2019;44(6):970–973.
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Benotti JR, Alpert JS, et al. Pharmacokinetics of intravenous bepridil in patients with coronary disease. J Pharm Sci. 1986;75(10):952–954.
   PubMed Web of Science ®Google Scholar
• Pritchard JF, McKown LA, Dvorchik BH, et al. Plasma protein binding of bepridil. J Clin Pharmacol. 1985;25(5):347–353.
   PubMed Web of Science ®Google Scholar
• Awni WM, Halstenson CE, Nayak RK, et al. Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease. J Clin Pharmacol. 1995;35(4):379–383.
   PubMed Web of Science ®Google Scholar
• Hermann P, Rodger SD, Remones G, Thenot JP, London DR, et al. Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol. 1983;24(3):349–352.
   PubMed Web of Science ®Google Scholar
• Dias VC, Weir SJ, Ellenbogen KA. Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter. Circulation. 1992;86(5):1421–1428.
   PubMed Web of Science ®Google Scholar
• Bianchetti G, Dubruc C, Sultana V, et al. Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers. Eur J Clin Pharmacol. 1995;48(3–4):259–264.
   PubMed Web of Science ®Google Scholar
• Kwong TC, Sparks JD, Sparks CE. Lipoprotein and protein binding of the calcium channel blocker diltiazem. Proc Soc Exp Biol Med. 1985;178(2):313–316.
   PubMed Web of Science ®Google Scholar
• Jaeger A, Sauder P, Bianchetti G, et al. Acute diltiazem poisoning: kinetic and hemodynamics study. J Toxicol Clin Exp. 1990;10(4):243–248.
   PubMedGoogle Scholar
• Roberts D, Honcharik N, Sitar DS, et al. Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy. J Toxicol Clin Toxicol. 1991;29(1):45–52.
   PubMed Web of Science ®Google Scholar
• Connolly DL, Nettleton MA, Bastow MD. Massive diltiazem overdose. Am J Cardiol. 1993;72(9):742–743.
   PubMed Web of Science ®Google Scholar
• Erickson FC, Ling LJ, Grande GA, et al. Diltiazem overdose: case report and review. J Emerg Med. 1991;9(5):357–366.
   PubMedGoogle Scholar
• Snook CP, Sigvaldason K, Kristinsson J. Severe atenolol and diltiazem overdose. J Toxicol Clin Toxicol. 2000;38(6):661–665.
   PubMed Web of Science ®Google Scholar
• Ferner RE, Odemuyiwa O, Field AB, et al. Pharmacokinetics and toxic effects of diltiazem in massive overdose. Hum Toxicol. 1989;8(6):497–499.
   PubMedGoogle Scholar
• Buffet M, Ostermann G, Raclot P, et al. Kinetics of diltiazem in voluntary overdosage]. Presse Med. 1984;13(21):1338.
   PubMed Web of Science ®Google Scholar
• Malcolm N, Callegari P, Goldberg J, et al. Massive diltiazem overdosage: clinical and pharmacokinetic observations. Drug Intell Clin Pharm. 1986;20(11):888.
   PubMedGoogle Scholar
• Edgar B, Regardh CG, Johnsson G, et al. Felodipine kinetics in healthy men. Clin Pharmacol Ther. 1985;38(2):205–211.
   PubMed Web of Science ®Google Scholar
• Landahl S, Edgar B, Gabrielsson M, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. Clin Pharmacokinet. 1988;14(6):374–383.
   PubMed Web of Science ®Google Scholar
• Dunselman PH, Edgar B, Scaf AH, et al. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Br J Clin Pharmacol. 1989;28(1):45–52.
   PubMed Web of Science ®Google Scholar
• Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997;52(2):139–145.
   PubMed Web of Science ®Google Scholar
• Scaf AH, Dunselman PH, Wesseling H. Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients. Eur J Clin Pharmacol. 1995;49(3):203–210.
   PubMed Web of Science ®Google Scholar
• Cotting J, Reichen J, Kutz K, et al. Pharmacokinetics of isradipine in patients with chronic liver disease. Eur J Clin Pharmacol. 1990;38(6):599–603.
   PubMed Web of Science ®Google Scholar
• Alonso C, Deye N, Voicu S, et al. Nicardipine poisoning in the intensive care unit: management, outcome and toxicokinetics. Clin Toxicol. 2020;58(6):624.
   Web of Science ®Google Scholar
• Clifton GD, Blouin RA, Dilea C, et al. The pharmacokinetics of oral isradipine in normal volunteers. J Clin Pharmacol. 1988;28(1):36–42.
   PubMed Web of Science ®Google Scholar
• Schonholzer K, Marone C. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol. 1992;42(2):231–233.
   PubMed Web of Science ®Google Scholar
• Higuchi S, Shiobara Y. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica. 1980;10(6):447–454.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Dow RJ, Hall DJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol. 1985;20(Suppl 1):23S–28S.
   PubMed Web of Science ®Google Scholar
• Wagner JG, Ling TL, Mroszczak EJ, et al. Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects. Biopharm Drug Dispos. 1987;8(2):133–148.
   PubMed Web of Science ®Google Scholar
• Guerret M, Cheymol G, Hubert M, et al. Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. Eur J Clin Pharmacol. 1989;37(4):381–385.
   PubMed Web of Science ®Google Scholar
• Cook E, Clifton GG, Vargas R, et al. Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine. Clin Pharmacol Ther. 1990;47(6):706–718.
   PubMed Web of Science ®Google Scholar
• Modi NB, Veng-Pedersen P, Graham DJ, et al. Application of a system analysis approach to population pharmacokinetics and pharmacodynamics of nicardipine hydrochloride in healthy males. J Pharm Sci. 1993;82(7):705–713.
   PubMed Web of Science ®Google Scholar
• Cheung AT, Guvakov DV, Weiss SJ, et al. Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function. Anesth Analg. 1999;89(5):1116–1123.
   PubMed Web of Science ®Google Scholar
• Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther. 1984;35(6):742–749.
   PubMed Web of Science ®Google Scholar
• Kleinbloesem CH, van Brummelen P, Faber H, et al. Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. J Cardiovasc Pharmacol. 1987;9(2):202–208.
   PubMed Web of Science ®Google Scholar
• van Bortel L, Bohm R, Mooij J, et al. Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure. Eur J Clin Pharmacol. 1989;37(2):185–189.
   PubMed Web of Science ®Google Scholar
• Robertson DR, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol. 1988;25(3):297–305.
   PubMed Web of Science ®Google Scholar
• Palma-Aguirre JA, Rosas-Alcazar G, Rodriguez JM, et al. Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers. Arch Invest Med. 1989;20(2):129–135.
   PubMedGoogle Scholar
• Walley TJ, Heagerty AM, Woods KL, et al. Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers. Br J Clin Pharmacol. 1987;23(6):693–701.
   PubMed Web of Science ®Google Scholar
• Ferner RE, Monkman S, Riley J, et al. Pharmacokinetics and toxic effects of nifedipine in massive overdose. Hum Exp Toxicol. 1990;9(5):309–311.
   PubMed Web of Science ®Google Scholar
• Ramsch KD, Ahr G, Tettenborn D, et al. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia. 1985;28(Suppl 1):74–78.
   PubMedGoogle Scholar
• Vinge E, Andersson KE, Brandt L, et al. Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421–425.
   PubMed Web of Science ®Google Scholar
• Kumana CR, Kou M, Yu YL, et al. Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. Eur J Clin Pharmacol. 1993;45(4):363–366.
   PubMed Web of Science ®Google Scholar
• Blardi P, Urso R, De LA, et al. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin Pharmacol Ther. 2002;72(5):556–561.
   PubMed Web of Science ®Google Scholar
• Kirch W, Ramsch KD, Duhrsen U, et al. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res. 1984;4(5):381–384.
   PubMedGoogle Scholar
• van Harten J, van Brummelen P, Zeegers RR, et al. The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. Br J Clin Pharmacol. 1988;25(6):709–717.
   PubMed Web of Science ®Google Scholar
• van Harten J, van Brummelen P, Danhof M, et al. Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. J Cardiovasc Pharmacol. 1989;13(4):624–629.
   PubMed Web of Science ®Google Scholar
• van Harten J, van Brummelen P, Ooms P, et al. Variability in the pharmacokinetics of nisoldipine as caused by differences in liver blood flow response. J Clin Pharmacol. 1989;29(8):714–721.
   PubMed Web of Science ®Google Scholar
• van Harten J, van Brummelen P, Lodewijks MT, et al. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. Clin Pharmacol Ther. 1988;43(3):332–341.
   PubMed Web of Science ®Google Scholar
• Boelaert J, Valcke Y, Dammekens H, et al. Pharmacokinetics of nisoldipine in renal dysfunction. Eur J Clin Pharmacol. 1988;34(2):207–209.
   PubMed Web of Science ®Google Scholar
• Ramsch KD, Graefe KH, Scherling D, et al. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol. 1986;6(Suppl 1):73–80.
   PubMed Web of Science ®Google Scholar
• van Bortel L, Bohm R, Mooy J, et al. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol. 1989;36(5):467–471.
   PubMed Web of Science ®Google Scholar
• Mikus G, Fischer C, Heuer B, et al. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. Br J Clin Pharmacol. 1987;24(5):561–569.
   PubMed Web of Science ®Google Scholar
• Soons PA, Breimer DD. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. Br J Clin Pharmacol. 1991;32(1):11–16.
   PubMed Web of Science ®Google Scholar
• Ankermann T, Osterkamp U, Santos SR, et al. Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. Eur J Clin Pharmacol. 1989;36(5):433–437.
   PubMed Web of Science ®Google Scholar
• Kierdorf H, Müller A, Blanke PM, et al. Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure. Eur J Clin Pharmacol. 1993;45(2):129–134.
   PubMed Web of Science ®Google Scholar
• Kates RE, Keefe DL, Schwartz J, et al. Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther. 1981;30(1):44–51.
   PubMed Web of Science ®Google Scholar
• Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40(3):219–230.
   PubMed Web of Science ®Google Scholar
• Koike Y, Shimamura K, Shudo I, et al. Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol. 1979;24(1):37–47.
   PubMedGoogle Scholar
• Dominic JA, Bourne DW, Tan TG, et al. The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol. 1981;3(1):25–38.
   PubMed Web of Science ®Google Scholar
• Somogyi A, Albrecht M, Kliems G, et al. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol. 1981;12(1):51–60.
   PubMed Web of Science ®Google Scholar
• Anderson P, Bondesso NU, Sylven C. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. Eur J Clin Pharmacol. 1982;23(1):49–57.
   PubMed Web of Science ®Google Scholar
• Reiter MJ, Shand DG, Aanonsen LM, et al. Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. Am J Cardiol. 1982;50(4):716–721.
   PubMed Web of Science ®Google Scholar
• Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984;17(4):453–458.
   PubMed Web of Science ®Google Scholar
• Mooy J, Arends B, van Kemenade J, et al. Influence of prolonged submaximal exercise on the pharmacokinetics of verapamil in humans. J Cardiovasc Pharmacol. 1986;8(5):940–942.
   PubMed Web of Science ®Google Scholar
• Schoen MD, Parker RB, Hoon TJ, et al. Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. Am J Cardiol. 1991;67(4):300–304.
   PubMed Web of Science ®Google Scholar
• Berk SI, Beckman K, Hoon TJ, et al. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. Pharmacotherapy. 1992;12(1):33–39.
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1994;55(5):509–517.
   PubMed Web of Science ®Google Scholar
• Keefe DL, Yee YG, Kates RE. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther. 1981;29(1):21–26.
   PubMed Web of Science ®Google Scholar
• Sauder P, Kopferschmitt J, Dahlet M, et al. Acute verapamil poisoning. 6 cases. Review of the literature. J Toxicol Clin Exp. 1990;10(4):261–270.
   PubMedGoogle Scholar
• Megarbane B, Karyo S, Abidi K, et al. Predictors of mortality in verapamil overdose: usefulness of serum verapamil concentrations. Basic Clin Pharmacol Toxicol. 2011;108(6):385–389.
   PubMed Web of Science ®Google Scholar
• Cole JB, Arens AM, Laes JR, et al. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am J Emerg Med. 2018;36(10):1817–1824.
   PubMed Web of Science ®Google Scholar
• Hetterich N, Lauterbach E, Sturer A, et al. Toxicity of antihypertensives in unintentional poisoning of young children. J Emerg Med. 2014;47(2):155–162.
   PubMed Web of Science ®Google Scholar
• Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med. 1990;19(6):649–653.
   PubMed Web of Science ®Google Scholar
• Christensen MB, Petersen KM, Bogevig S, Al-Gibouri S, et al. Outcomes following calcium channel blocker exposures reported to a poison information center. BMC Pharmacol Toxicol. 2018;19(1):78.
   PubMed Web of Science ®Google Scholar
• Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med. 1993;95(4):431–438.
   PubMed Web of Science ®Google Scholar
• Levine M, Curry S, Padilla-Jones A, et al. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med. 2013;62(3):252–258.
   PubMed Web of Science ®Google Scholar
• Lashari BH, Minalyan A, Khan W, et al. the use of high-dose insulin infusion and lipid emulsion therapy in concurrent beta-blocker and calcium channel blocker overdose. Cureus. 2018;10(11):e3534.
   PubMed Web of Science ®Google Scholar
• Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. 1994;13(3):161–166.
   PubMed Web of Science ®Google Scholar
• Deters M, Bergmann I, Enden G, et al. Calcium channel antagonist exposures reported to the Poisons Information Center Erfurt. Eur J Intern Med. 2011;22(6):616–620.
   PubMed Web of Science ®Google Scholar
• Espinoza TR, Bryant SM, Aks SE. Hyperinsulin therapy for calcium channel antagonist poisoning: A seven-year retrospective study. Am J Ther. 2013;20(1):29–31.
   PubMed Web of Science ®Google Scholar
• Chen C, Voicu S, Diallo A, et al. The severity and mortality prediction of calcium-channel blocker poisoning in the intensive care unit. Clin Toxicol. 2020;58(6):508.
   Web of Science ®Google Scholar
• Huang J, Isoardi K, Buckley N, et al. Angiotensin axis antagonists increase the severity of dihydropyridine poisoning. Clin Toxicol. 2020;58(6):616–617.
   Web of Science ®Google Scholar
• Belson MG, Gorman SE, Sullivan K, et al. Calcium channel blocker ingestions in children. Am J Emer Med. 2000;18(5):581–586.
   PubMed Web of Science ®Google Scholar
• Benson BE, Spyker DA, Troutman WG, et al. Amlodipine toxicity in children less than 6 years of age: a dose-response analysis using national poison data system data. J Emer Med . 2010;39(2):186–193.
   PubMed Web of Science ®Google Scholar
• Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071–2075.
   PubMed Web of Science ®Google Scholar
• Lambert H, Weber M, Renaud D. Acute diltiazem (DTZ) poisoning. Survey of French Poison Control Centers. J. 1990;10(4):229–242.
   Google Scholar
• Clifton GD, Booth DC, Hobbs S, et al. Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels. Am Heart J. 1990;119(2 Pt 1):283–290.
   PubMed Web of Science ®Google Scholar
• Materne P, Legrand V, Vandormael M, et al. Hemodynamic effects of intravenous diltiazem with impaired left ventricular function. Am J Cardiol. 1984;54(7):733–737.
   PubMed Web of Science ®Google Scholar
• Roper TA, Sykes R, Gray C. Fatal diltiazem overdose: report of four cases and review of the literature. Postgrad Med J. 1993;69(812):474–476.
   PubMed Web of Science ®Google Scholar
• St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014;52(9):926–944.
   PubMed Web of Science ®Google Scholar
• Cumpston KL, Aks SE, Sigg T, et al. Whole bowel irrigation and the hemodynamically unstable calcium channel blocker overdose: primum non nocere. J Emerg Med. 2010;38(2):171–174.
   PubMed Web of Science ®Google Scholar
• Buckley N, Dawson AH, Howarth D, et al. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust. 1993;158(3):202–204.
   PubMed Web of Science ®Google Scholar
• Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33(11):2019–2024.
   PubMed Web of Science ®Google Scholar
• McGlinchey PG, McNeill AJ. Drug overdoses requiring temporary cardiac pacing; a study of six cases treated at Altnagelvin Hospital, Londonderry. Ulster Med J. 1998;67(1):13–18.
   PubMedGoogle Scholar
• Masson R, Colas V, Parienti JJ, et al. A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication. Resuscitation. 2012;83(11):1413–1417.
   PubMed Web of Science ®Google Scholar
• Weiner L, Mazzeffi M, Hines E, et al. Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the Extracorporeal Life Support Organizations' ECMO case registry. Clin Tox. 2020;58(7):705–710.
   PubMed Web of Science ®Google Scholar
• Gosselin S, Hoegberg LC, Hoffman RS, Graudins A, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clin Toxicol. 2016;54(10):899–923.
   PubMed Web of Science ®Google Scholar
• ter Wee PM, Kremer Hovinga TK, Uges DR, et al. 4-Aminopyridine and haemodialysis in the treatment of verapamil intoxication. Hum Toxicol. 1985;4(3):327–329.
   PubMedGoogle Scholar
• Siebenlist D. Plasma separation in verapamil poisoning. Dtsch Med Wochenschr. 1990;115(20):797.
   PubMed Web of Science ®Google Scholar
• Rosansky SJ. Verapamil toxicity-treatment with hemoperfusion. Ann Intern Med. 1991;114(4):340–341.
   PubMed Web of Science ®Google Scholar
• Zobel G, Stein J, Udermann H. Severe verapamil intoxication in an adolescent female. Clin Intens Care. 1991;2(2):109–110.
   Google Scholar
• Welch CD, Knoerzer RE, Lewis GS. Verapamil and acebutolol overdose results in asystole: intra-aortic balloon pump provides mechanical support. J Extra-Corp Technol. 1992;24(1):36–37.
   Google Scholar
• Gutschmidt HJ. Successful plasmapheresis in severe diltiazem poisoning. Dtsch Med Wochenschr. 1995;120(3):81–82.
   PubMed Web of Science ®Google Scholar
• Van Wanroy JL, De Weerdt O, Joore JCA, et al. Drug overdose with slow release. Nederlands Tijdschrift Voor Geneeskunde. 1996;140(1):16–18.
   PubMedGoogle Scholar
• Williamson KM, Dunham GD. Plasma concentrations of diltiazem and desacetyldiltiazem in an overdose situation. Ann Pharmacother. 1996;30(6):608–611.
   PubMed Web of Science ®Google Scholar
• Martin-Gago J, Pascual J, Rodriguez-Palomares JR, Marcen R, et al. Complete atrioventricular blockade secondary to conventional-release verapamil in a patient on hemodialysis [3]. Nephron. 1999;83(1):89–90.
   PubMed Web of Science ®Google Scholar
• Kuhlmann U, Schoenemann H, Muller T, et al. Plasmapheresis in life-threatening verapamil intoxication. Artif Cells Blood Substit Immobil Biotechnol. 2000;28(5):429–440.
   PubMed Web of Science ®Google Scholar
• Harley C, Kannan S, Morrow B. Combined overdose with bisoprolol, nifedipine and diltiazem. Care Crit Ill. 2001;17(2):65–66.
   Google Scholar
• Marraffa JM, Stork CM, Medicis JJ, et al. Massive amlodipine overdose successfully treated using high-dose vasopressin. Clin Toxicol. 2004;42(5):732–733.
   Google Scholar
• Tan CKD, Chan BSH, Nanavati Z, et al. Extracorporeal albumin dialysis does not reduce serum drug concentrations after overdose with sustained-release verapamil. Clin Toxicol. 2004;42(5):718–719.
   Google Scholar
• Maclaren G, Butt W, Cameron P, et al. Treatment of polypharmacy overdose with multimodality extracorporeal life support. Anaesth Intens Care. 2005;33(1):120–123.
   PubMed Web of Science ®Google Scholar
• Kolcz J, Pietrzyk J, Januszewska K, et al. Extracorporeal life support in severe propranolol and verapamil intoxication. J Intensive Care Med. 2007;22(6):381–385.
   PubMedGoogle Scholar
• Ezidiegwu C, Spektor Z, Nasr MR, et al. A case report on the role of plasma exchange in the management of a massive amlodipine besylate intoxication. Ther Apher Dial. 2008;12(2):180–184.
   PubMed Web of Science ®Google Scholar
• Pfaender M, Casetti PG, Azzolini M, et al. Successful treatment of a massive atenolol and nifedipine overdose with CVVHDF. Minerva Anestesiol. 2008;74(3):97–100.
   PubMed Web of Science ®Google Scholar
• Aaronson PM, Wassil SK, Kunisaki TA. Hyperinsulinemic euglycemia, continuous veno-venous hemofiltration, and extracorporeal life support for severe verapamil poisoning: case report. Clin Toxicol. 2009;47(7):742.
   Web of Science ®Google Scholar
• Rahman O, Craft M, Mainali R, et al. Massive diltiazem overdose treated with continuous veno-venous hemodiafiltration (CVVH/DF). Critic Care Med. 2009;37(12):A511.
   Web of Science ®Google Scholar
• Deters M, Friesecke S, Hentschel H. Fatal poisoning caused by felodipine. Clin Toxicol. 2010;48(3):281.
   Web of Science ®Google Scholar
• Kute VB, Shah PR, Goplani KR, et al. Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine. Indian J Crit Care Med. 2011;15(3):182–184.
   PubMedGoogle Scholar
• Rona R, Cortinovis B, Marcolin R, et al. Extra-corporeal life support for near-fatal multi-drug intoxication: a case report. J Med Case Rep. 2011;5:231.
   PubMedGoogle Scholar
• Maldonado I, Johnson M, Crawford A, et al. Beta blockers and calcium-channel blockers overdose: time to abandon a silver-bullet approach critical care medicine. 2012;40(12):301.
   Google Scholar
• Pichon N, Dugard A, Clavel M, et al. Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock. Ann Emerg Med. 2012;59(6):540–544.
   PubMed Web of Science ®Google Scholar
• Turhan KS, Oral M, Unal N, et al. Selective plasma exchange with evaclio in a patient with angiotensin receptor blocker and calcium channel blocker intoxication. Transf Apheresis Sci. 2012;47:S50–S1.
   Google Scholar
• Kalimullah F, Lee S, Nelson D. Diltiazem levels after overdose in the setting of multiorgan failure and extracorporeal support. Crit Care Med. 2013;41(12):A338.
   Web of Science ®Google Scholar
• Garg SK, Goyal PK, Kumar R, et al. Management of life-threatening calcium channel blocker overdose with continuous veno-venous hemodiafiltration with charcoal hemoperfusion. Indian J Crit Care Med. 2014;18(6):399–401.
   PubMedGoogle Scholar
• Koschny R, Lutz M, Seckinger J, et al. Extracorporeal life support and plasmapheresis in a case of severe polyintoxication. J Emerg Med. 2014;47(5):527–531.
   PubMed Web of Science ®Google Scholar
• Nasa P, Singh A, Juneja D, et al. Continuous venovenous hemodiafiltration along with charcoal hemoperfusion for the management of life-threatening lercanidipine and amlodipine overdose. Saudi J Kidney Dis Transpl. 2014;25(6):1255–1258.
   PubMedGoogle Scholar
• Sacks L, Hussain E. Plasmapheresis significantly reduces serum amlodipine levels following intentional overdose. Crit Care Med. 2014;42(12):A1631.
   Web of Science ®Google Scholar
• Sandeep P, Ram R, Sowgandhi N, et al. Atenolol and amlodipine combination overdose managed with continuous venovenous hemodiafiltration: a case report. Indian J Nephrol. 2014;24(5):327–329.
   PubMedGoogle Scholar
• Gerard L, Galloy AC, Capron A, et al. Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). Clin Toxicol. 2015;53(6):573–577.
   Web of Science ®Google Scholar
• Eldred J, Evans M, Bridgman B, et al. Reversal of calcium channel blocker toxicity with molecular adsorbents recirculating system. Crit Care Med . 2016;44(12 Supplement 1):499.
   Web of Science ®Google Scholar
• Magreault S, Vodovar D, Deye N, et al. Life-threatening amlodipine intoxication: a comparison of two approaches to treatment. Clin Toxicol. 2016;54:474.
   Web of Science ®Google Scholar
• Reuter-Rice KE, Peterson BM. Conventional and unconventional lifesaving therapies in an adolescent with amlodipine ingestion. Crit Care Nurse. 2016;36(4):64–69.
   PubMed Web of Science ®Google Scholar
• Scott S, Messer B. Use of 20% intralipid in the management of a haemodynamically unstable patient following a mixed overdose. Anaesthesia. 2016;71(S2):57.
   PubMed Web of Science ®Google Scholar
• Chudow M, Ferguson K. A case of severe, refractory hypotension after amlodipine overdose. Cardiovasc Toxicol. 2018;18(2):192–197.
   PubMed Web of Science ®Google Scholar
• G, Martinez JJ, Mollard F, Baud F, et al. Intoxication with calcium channel blockers and other highly protein-bound drugs: why use MARS? Two clinical case reports. J Clin Toxicol. 2018;8(3):1–7.
   Google Scholar
• Seegobin K, Maharaj S, Deosaran A, et al. Severe beta blocker and calcium channel blocker overdose: role of high dose insulin. Am J Emerg Med. 2018;36(4):736 e5–e6.
   Web of Science ®Google Scholar
• Pinto VL, Wenderfer SE, Morris J, et al. Treatment of severe amlodipine toxicity with molecular adsorbent recirculating system. Kidney Int Rep. 2019;4(2):346–349.
   PubMed Web of Science ®Google Scholar
• Connor-Schuler RL, Carr JM, Reaven MS, et al. The efficacy of albumin dialysis in the reversal of refractory vasoplegic shock due to amlodipine toxicity. Crit Care Explor. 2020;2(6):e0120.
   PubMedGoogle Scholar
• Schmidt J, Busch M, David S, et al. Treatment of life-threatening amlodipine poisoning with ECMO support, HCO dialysis and Cytosorb® adsorber. Conference abstract (Nephrologie 2020). 2020.
   Google Scholar
• Yeşilbaş O, Ramoğlu MG, Çayan ÖK, et al. Successful single-pass albumin dialysis in the management of severe calcium channel blocker poisoning. Turk Pediatri Ars. 2020;55(1):82–84.
   PubMedGoogle Scholar
• Sutterlin L, Malissin I, Voicu S, et al. Management of severe calcium channel blocker poisonings using albumin dialysis by MARS™: benefits and limits. Clin Toxicol. 2019;57(6):532–533.
   Web of Science ®Google Scholar
• Okura T. The metabolism and clinical effects of nicardipine hydrochloride in patients with chronic renal failure and hemodialysis patients [Japanese]. Jap Pharmacol Therap. 1983;11(12):99–106.
   Google Scholar
• Bogaert MG, Rosseel MT, Joos R, et al. Plasma concentrations of nifedipine in patients with renal failure. Arzneimittelforschung. 1984;34(3):307–308.
   PubMed Web of Science ®Google Scholar
• Singlas E, Martre H, Taburet AM, et al. Effect of hemodialysis on plasma levels of nifedipine. Presse Med. 1984;13(15):943–944.
   PubMed Web of Science ®Google Scholar
• Clair F, Bellet M, Guerret M. Hypotensive effect and pharmacokinetics of nicardipine in patients with severe renal failure. Curr Therap Res Clin Exp. 1985;38(1):74–82.
   Web of Science ®Google Scholar
• Shah GM, Winer RL. Verapamil kinetics during maintenance hemodialysis. Am J Nephrol. 1985;5(5):338–341.
   PubMed Web of Science ®Google Scholar
• Kleinbloesem CH, van Brummelen P, Woittiez AJ, et al. Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion. Clin Pharmacokinet. 1986;11(4):316–322.
   PubMed Web of Science ®Google Scholar
• Grech-Belanger O, Langlois S, LeBoeuf E. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. J Clin Pharmacol. 1988;28(5):477–480.
   PubMed Web of Science ®Google Scholar
• Beyerlein C, Csaszar G, Hollmann M, et al. Verapamil in antihypertensive treatment of patients on renal replacement therapy–clinical implications and pharmacokinetics. Eur J Clin Pharmacol. 1990;39(S1):S35–S7.
   PubMed Web of Science ®Google Scholar
• Welker HA, Weidekamm E, Houwing N, et al. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency. Pharmacology. 1998;56(6):297–307.
   PubMed Web of Science ®Google Scholar
• Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol. 2003;59(4):291–295.
   PubMed Web of Science ®Google Scholar
• Kojima M, Taniguchi M, Sato K, et al. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days-a randomized crossover trial between benidipine and nifedipine CR. Nephron Clin Pract. 2004;97(2):c49–c53.
   PubMedGoogle Scholar
• Forster V, Signorell RD, Roveri M, et al. Liposome-supported peritoneal dialysis for detoxification of drugs and endogenous metabolites. Sci Transl Med. 2014;6(258):258ra141.
   PubMed Web of Science ®Google Scholar
• Caill N, Baud F, Jouffroy R, et al. Comparative extractive efficiency of continuous veno-venous hemodiafiltration (CVVHDF) and molecular adsorbent recirculating system (MARS) in simulated verapamil poisoning: an ex vivo study. Clin Toxicol. 2017;55(5):424.
   Web of Science ®Google Scholar
• Chan PP, Young WT, Capponi V, et al. A novel adsorbent system rapidly clears verapamil from human blood. Acad Emer Med . 2016;1:S229–S30.
   Google Scholar
• Chan PP, Young WT, Capponi V, et al. A novel adsorbent system rapidly clears amlodipine from human blood. Acad Emer Med. 2016;1:S45–S6.
   Google Scholar
• Jouffroy R, Nicolas C, Philippe P, et al. Purifying efficiency of CVVHDF and MARS in a simulated poisoning by verapamil. Ann Inten Care. 2017;7(1 Supplement 1):87–88.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Yuda R, Amano F, et al. Comparative studies of dialyzability of levofloxacin and amlodipine using in vitro dialysis system with three different types of dialyzers. J Health Sci. 1999;45(5):271–275.
   Google Scholar
• Nakanishi Y, Inagaki O, Hiwasa K, et al. Adsorption of charged drugs by dialysis membranes [Japanese]. Jap J Artif Organs. 1996;25(1):113–116.
   Google Scholar
• Ghannoum M, Hoffman RS, Gosselin S, et al. Use of extracorporeal treatments in the management of poisonings. Kidney Int. 2018;94(4):682–688.
   PubMed Web of Science ®Google Scholar
• Roberts DM, Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet. 2007;46(11):897–939.
   PubMed Web of Science ®Google Scholar
• Tawashi M, Marc-Aurele J, Bichet D, et al. Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure. Biopharm Drug Dispos. 1991;12(2):95–104.
   PubMed Web of Science ®Google Scholar
• Bouchard J, Lavergne V, Roberts DM, et al. Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey. Nephrol Dial Transplant. 2017;32(4):699–706.
   PubMed Web of Science ®Google Scholar
• Vodovar D, Megarbane B. Could extracorporeal albumin dialysis be considered as an adjunct therapy in calcium channel blocker overdose? Neth J Med. 2016;74(6):277–278.
   PubMed Web of Science ®Google Scholar
• Guo LM, Liu JY, Xu DZ, et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int. 2003;23(Suppl 3):16–20.
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care. 2006;10(6):R169.
   PubMed Web of Science ®Google Scholar
• Sebe A, Dişel NR, Açıkalın Akpınar A, et al. Role of intravenous lipid emulsions in the management of calcium channel blocker and β-blocker overdose: 3 years experience of a university hospital. Postgrad Med. 2015;127(2):119–124.
   PubMed Web of Science ®Google Scholar
• Brass P, Hellmich M, Kolodziej L, et al. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev. 2015;1:CD011447.
   PubMedGoogle Scholar
• Brass P, Hellmich M, Kolodziej L, et al. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. Cochrane Database Syst Rev. 2015;1:CD006962.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Mongardon N, Megarbane B, 3SITES Study Group, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373(13):1220–1229.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Na HS, Koh WU, et al. Complications in internal jugular vs subclavian ultrasound-guided central venous catheterization: a comparative randomized trial. Intensive Care Med. 2019;45(7):968–976.
   PubMed Web of Science ®Google Scholar
• Bjorkander M, Bentzer P, Schott U, et al. Mechanical complications of central venous catheter insertions: a retrospective multicenter study of incidence and risks. Acta Anaesthesiol Scand. 2019;63(1):61–68.
   PubMed Web of Science ®Google Scholar
• Wong B, Zimmerman D, Reintjes F, et al. Procedure-related serious adverse events among home hemodialysis patients: a quality assurance perspective. Am J Kidney Dis. 2014;63(2):251–258.
   PubMed Web of Science ®Google Scholar
• Tennankore KK, d'Gama C, Faratro R, et al. Adverse technical events in home hemodialysis. Am J Kidney Dis. 2015;65(1):116–121.
   PubMed Web of Science ®Google Scholar
• Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817–827.
   PubMed Web of Science ®Google Scholar
• Sutton DM, Nair RC, Rock G. Complications of plasma exchange. Transfusion. 1989;29(2):124–127.
   PubMed Web of Science ®Google Scholar
• Yang X, Xin S, Zhang Y, et al. Early hemoperfusion for emergency treatment of carbamazepine poisoning. Am J Emerg Med. 2018;36(6):926–930.
   PubMed Web of Science ®Google Scholar
• Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med. 1997;4(7):674–678.
   PubMed Web of Science ®Google Scholar
• Gummin DD, Mowry JB, Spyker DA, et al. Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual report. Clin Toxicol. 2017;2018:1–203.
   Google Scholar